II. Indications

  1. See NSAID
  2. FDA approved indications in Adults
    1. Mild to moderate pain
    2. Dysmenorrhea
    3. Menorrhagia
    4. Osteoarthritis
    5. Rheumatoid Arthritis
  3. Non-FDA approved indications in children (off-label use)
    1. Juvenile Rheumatoid Arthritis

III. Contraindications

  1. See NSAID

IV. Mechanism

  1. See NSAID
  2. Anthranilic Acid NSAID in the Fenamate Class

V. Medications

  1. Meclofenamate capsules 50 mg, 100 mg

VI. Dosing: Adults

  1. Mild to moderate pain
    1. Meclofenamate 50 mg orally every 4 to 6 hours
  2. Primary Dymenorrhea
    1. Meclofenamate 100 mg orally every 8 hours for up to 6 days
  3. Arthritis (OA, RA)
    1. Meclofenamate 200 to 400 mg/day divided 3-4 times daily

VII. Dosing: Child

  1. Juvenile Rheumatoid Arthritis (not FDA approved)
    1. Meclofenamate 3 to 7.5 mg/kg/day (max: 300 mg/day) orally in divided doses

VIII. Adverse Effects

  1. See NSAID
  2. Autoimmune Hemolytic Anemia
    1. Associated with prolonged use >1 year
  3. Diarrhea
    1. Occurs in up to 35% of patients

IX. Safety

  1. See NSAID
  2. Avoid in Lactation
  3. Avoid NSAIDs in pregnancy outside the first part of the second trimester (13 to 20 weeks)
    1. Teratogenic in first trimester
    2. Risk of premature ductus arteriosus closure in the fetus in third trimester
    3. Most NSAIDs carry a legacy system Pregnancy Category B or C designation (aside from third trimester)
      1. However, many obstetricians avoid NSAIDs entirely in pregnancy (even in second trimester)

X. Efficacy

  1. Comparable to Aspirin in its Analgesic effects

XII. References

  1. Hamilton (2020) Tarascon Pocket Pharmacopoeia

Images: Related links to external sites (from Bing)

Related Studies

Ontology: Meclofenamate Sodium (C0025041)

Definition (NCI) The sodium salt form of meclofenamate, an anthranilic acid and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Meclofenamate sodium inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis, by prostaglandin synthase, is responsible for the therapeutic effects of meclofenamate sodium. Meclofenamate sodium also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH D008469
SnomedCT 58233009, 363610001
English Meclofenamate, Sodium, Sodium Meclofenamate, Sodium, Meclofenamate, Benzoic Acid, 2-((2,6-dichloro-3-methylphenyl)amino)-, Monosodium Salt, Meclonax, Sodium 2-((2,6-dichloro-3-methylphenyl)amino)benzoate, meclofenamate sodium (medication), meclofenamate sodium, MECLOFENAMATE SODIUM, Meclofenamate Sodium, Meclofenamate Sodium [Chemical/Ingredient], Meclofenamate Sodium Salt, Meclofenamate sodium, Meclofenamate sodium (substance), Meclofenamate sodium product (product), Meclofenamate sodium product, Meclofenamate sodium product (substance)
German Natrium-Meclofenamat, Meclofenamat-Natrium
Spanish meclofenamato sódico (producto), meclofenamato sódico, producto (producto), meclofenamato sódico, producto, meclofenamato sódico (sustancia), meclofenamato sódico
French Méclofénamate de sodium

Ontology: Meclofenamate (C1289957)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH D008469
SnomedCT 117178002
LNC LP18481-9, MTHU004498
English meclofenamate, MECLOFENAMATE, Meclofenamate [Chemical/Ingredient], Meclofenamate (substance), Meclofenamate
German Meclofenamat
French Méclofénamate
Spanish meclofenamato (sustancia), meclofenamato